Table 3.
Published clinical trials of immunotherapies modulating innate immunity in ovarian cancer patients.
| Intervention | NCT/Author | Phase | Enrollment | Primary Endpoint | PFS | OS | ORR |
|---|---|---|---|---|---|---|---|
| Dendritic Cell Vaccines (peptide target) | |||||||
| (Her2/neu + hTRT + PADRE) +/- cyclophosphamide |
Chu et al. | 1/2 | 14 OC in first or second remission | Safety and Activity | – | – | – |
| (WT p53 peptide) + IL-12 | Rahma et al. | 2 | 21 recurrent OC | Activity | 8.7 months | 29.6 months | – |
| (KLH) + IL-2 | Baek et al. | 1/2 | 10 with MRD | Safety and Activity | – | 65.0 months | 3/10 (30%) |
| (WT1) | Zhang et al. | 1/2 | 3 OC | DrAE | – | – | 0/3 (0%) |
| (Autologous tumor lysate) + KLH |
Hernando et al. | 1 | 6 progressive or recurrent OC | Safety and Activity | – | – | 0/6 (0%) |
| (Autologous tumor lysate) +/- bevacizumab +/-cyclophosphamide |
Tanyi et al. | 1? | 25 immunotherapy-naïve recurrent OC | Safety and Activity | – | – | 2/25 (8%) |
| Natural Killer Cells | |||||||
| NK Cells + IL-2 + CyFlu |
Geller et al. | 2 | 14 OC | Activity | – | – | 4/14 (28.5%) |
| Monocytes | |||||||
| Monocytes + IFNα/γ | Cole et al. | 1 | 11 recurrent OC | Safety and Activity | – | – | 2/11 (18.1%) |
-Not reported; RPR, recurrent platinum-sensitive; RPR, recurrent platinum-resistant; RP2D, Recommended phase 2 dose; ORR, Overall response rate; KLH, Keyhole limpet haemocyanin; hTRT, human telomerase reverse transcriptase; PADRE, pan-DR epitope; WT-1, Wilms’ tumor protein 1; CyFlu, Cyclophosphamide + Fludarabine; SQ, subcutaneous; MRD, minimal residual disease.